Trial Profile
Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Nalmefene (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- Acronyms NalmeCir
- 18 Jul 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 06 Aug 2018 Planned initiation date changed from 1 Jul 2016 to 1 Dec 2018.
- 13 Jul 2016 New trial record